<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antithrombin III deficient patients with manifest <z:hpo ids='HP_0001907'>thromboembolic diseases</z:hpo> need long term <z:chebi fb="2" ids="28794">coumarin</z:chebi> treatment </plain></SENT>
<SENT sid="1" pm="."><plain>There are contradictory data on the change of AT III during this therapy </plain></SENT>
<SENT sid="2" pm="."><plain>The authors observed 5 patients with severe AT III decrease type I, 3 with functional abnormality and 2 with a pathological <z:chebi fb="5" ids="28304">heparin</z:chebi> binding </plain></SENT>
<SENT sid="3" pm="."><plain>AT III function was determined by the Gerendás-Rák method and with chromogenic substrate </plain></SENT>
<SENT sid="4" pm="."><plain>AT III antigen was measured with Behring M-Partigen and Laurell rocket electrophoresis </plain></SENT>
<SENT sid="5" pm="."><plain>Crossed immunoelectrophoresis was carried out in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="6" pm="."><plain>In patients with type I AT III decrease, AT III hasn't changed even in a long period of more than 10 years </plain></SENT>
<SENT sid="7" pm="."><plain>In the other types AT III became <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>The pathological <z:chebi fb="5" ids="28304">heparin</z:chebi> binding wasn't changed </plain></SENT>
</text></document>